Oxidative damage in brains of mice treated with apomorphine and its oxidized derivative.
Increasing evidence suggests that some of the neurobiological and neurotoxic actions of apomorphine and other dopamine receptor agonists might be mediated by their oxidation derivatives. The aim of the present study was to evaluate the effects of apomorphine and its oxidation derivative, 8-oxo-apomorphine-semiquinone (8-OASQ), on oxidative stress parameters and antioxidant enzyme activity. Adult male CF-1 mice were treated with a systemic injection of apomorphine (0.4, 4.0 or 40.0 mg/kg) or 8-OASQ (0.4, 4.0 or 40.0 mg/kg). Animals were sacrificed by decapitation 24 h after treatment, and the forebrains were collected for analysis of thiobarbituric acid reactive species, protein carbonyls, the total radical-trapping antioxidant parameter, catalase and superoxide dismutase. These treatments did not induce lipid peroxidation at any dose tested. In contrast, apomorphine induced an increase in protein carbonylation and a decrease in total radical-trapping antioxidant parameter at all doses tested. 8-OASQ induced an increase in protein carbonylation and a decrease in total radical-trapping antioxidant parameter only at the higher dose tested. All apomorphine doses tested induced an increase in catalase, but not superoxide dismutase activities. In contrast, 8-OASQ induced a dose-dependent increase in CAT activity. The results suggest that apomorphine and its oxidation product, 8-OASQ, induce differential effects on CNS oxidative parameters.
Moreira
José Cláudio F
JC
Department of Biochemistry, ICBS, Federal University of Rio Grande do Sul (UFRGS), 90035-003, Porto Alegre, RS, Brazil. pegas@dna.cbiot.ufrgs.br
Dal-Pizzol
Felipe
F
Bonatto
Fernanda
F
da Silva
Evandro Gomes
EG
Flores
Débora G
DG
Picada
Jaqueline N
JN
Roesler
Rafael
R
Henriques
João Antonio Pêgas
JA
D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives* / Q000633:toxicity*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D002374:Catalase / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005609:Free Radicals / Q000378:metabolism; D008297:Male; D051379:Mice; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D011809:Quinones / Q000633:toxicity*; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D013858:Thiobarbiturates / Q000378:metabolism
C470323:8-oxo-apomorphine-semiquinone; D018491:Dopamine Agonists; D005609:Free Radicals; D011809:Quinones; D017382:Reactive Oxygen Species; D013858:Thiobarbiturates; D002374:Catalase; D013482:Superoxide Dismutase; C029684:thiobarbituric acid; D001058:Apomorphine